← Eichor
Condition: Cd7 Positive Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Cd7 Positive

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
Phase 2 · 16 location(s) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. · NCT07188610Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic Malignancies
EARLY_Phase 1 · 1 location(s) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. · NCT07338604CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases
Phase 1/Phase 2 · 1 location(s) · Zhejiang University · NCT05827835uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07109518Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT04033302Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07106723Universal 4SCAR7U Targeting CD7-positive Malignancies
Phase 1 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT05995028CD7-specific CAR-T Cell in the Treatment of CD7-positive Relapsed/Refractory Hematologic Tumors
Phase 1/Phase 2 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06720324Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells
Phase 1 · 2 location(s) · Baylor College of Medicine · NCT07220993RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies
Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06732492To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT
Phase 1 · 1 location(s) · Peking University People's Hospital · NCT07280494SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07153068To Observe the CD7-targeted CAR-T Therapy in the Treatment of r/r PTCL
Phase 1 · 1 location(s) · Peking University People's Hospital · NCT07143929Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT06420076
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.